Varda raises $250 million for orbital manufacturing missions
Official logo: Varda Space IndustriesVarda Space builds uncrewed capsules for research and manufacturing in microgravity, including pharmaceutical development. Reuters reports a $250 million Series D led by Lux Capital and Natural Capital at a $1.6 billion valuation. The company is scaling orbital missions, while clinical use of microgravity-enabled formulations remains a future milestone.
DTT summary based on Reuters's report. The full article is on the publisher's site.
Round details
Builds uncrewed orbital capsules for research and manufacturing in microgravity, including pharmaceutical development.
- Valuation: $1.6B.
- Funding supports orbital mission scale-up, not approval of microgravity-developed drugs.
- Series D raised: $250M
- Valuation: $1.6B
- Investors: Lux Capital, Natural Capital